SLC13A5-IN-1 NEW
| Price | $43 | $98 | $163 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: SLC13A5-IN-1 | CAS No.: 2227548-95-8 |
| Purity: 99.11% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | SLC13A5-IN-1 |
| Description | SLC13A5-IN-1 is a selective inhibitor of the sodium-citrate co-transporter (SLC13A5) that completely blocks the uptake of 14C-citrate, with an IC50 of 0.022 μM in HepG2 cells. |
| In vitro | In HepG2/14C-Citrate Uptake Assay,SLC13A5-IN-1 exhibits an IC50 of 0.022 μM . HepG2 cells endogenously express hSLC13A5 transporter which is responsible for the uptake of citrate into these cells. Uptake of 14C-citrate can be completely blocked by SLC13A5-IN-1 and the signal can be competed with unlabelled citrate.In recombinant hSLC3A5/14C-Citrate Uptake Assay, SLC13A5-IN-1 exhibits an IC50 of 0.056 μM . SLC13A5-IN-1 exhibits an IC50 of 100 μM in recombinant Human GlyT2/3H-Glycine Uptake Assay. The human embryonic kidney 293 cells are used that stably over-express the human GlyT2 receptor which is responsible for the uptake of glycine into these cells. Uptake of 3H-glycine can be completely blocked by SLC13A5-IN-1. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 5 mg/ml (10.83 mM), Sonication is recommended. |
| Keywords | hSLC3A5 | metabolic | SLC-13A5-IN-1 | SLC13A5IN1 | Inhibitor | SLC13A5-IN-1 | Citrate | SLC13A5 | cardiovascular | inhibit | disease | Sodium Channel | Uptake | Na channels | Na+ channels | SLC13A5 IN 1 |
| Inhibitors Related | Phenytoin sodium | Procaine | Lidocaine Hydrochloride hydrate | Lidocaine | Safinamide | Butamben | Lidocaine hydrochloride | L-Aspartic aicd sodium | Mebeverine hydrochloride | Amitriptyline hydrochloride | Riluzole | Benzocaine |
| Related Compound Libraries | Bioactive Compound Library | Inhibitor Library | Neuroprotective Compound Library | Metabolism Compound Library | Bioactive Compounds Library Max |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $34.00/1mg |
VIP5Y
|
TargetMol Chemicals Inc.
|
2024-11-15 | |
| $0.00/10mg |
VIP1Y
|
Hubei Chuchang Biotech Co., Ltd.
|
2024-10-29 | |
| $43.00/1mg |
VIP5Y
|
TargetMol Chemicals Inc.
|
2024-11-19 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY